Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder.
Biomarker
[123I]FP-CIT-SPECT
cardiac [123I]MIBG scintigraphy
hyposmia
isolated rapid eye movement sleep behavior disorder
prodromal progression marker
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
28
6
2022
medline:
9
9
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We investigated the use of cardiac [123I]meta-iodo-benzyl-guanidine scintigraphy ([123I]MIBG) and olfactory testing- in comparison to [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([123I]FP-CIT-SPECT)- for identifying iRBD patients as prodromal phenotype of PD/DLB. 37 RBD subjects underwent cardiac [123I]MIBG and brain [123I]FP-CIT-SPECT at baseline. Olfactory (Sniffin' Sticks), cognitive and motor functions were tested annually for ∼4 years. 29/37 (78.4%) subjects had a pathological [123I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [123I]FP-CIT-SPECT, always combined with a pathological [123I]MIBG. In subjects with pathological [123I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [123I]MIBG compared to those with normal [123I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [123I]MIBG and [123I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all- except for one- presented with at least moderate hyposmia at baseline. A combination of the biomarkers "pathological [123I]MIBG" and "hyposmia" likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [123I]MIBG had a normal [123I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [123I]MIBG, olfactory impairment is progressive independent of the [123I]FP-CIT-SPECT status.
Sections du résumé
BACKGROUND
Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
OBJECTIVE
We investigated the use of cardiac [123I]meta-iodo-benzyl-guanidine scintigraphy ([123I]MIBG) and olfactory testing- in comparison to [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([123I]FP-CIT-SPECT)- for identifying iRBD patients as prodromal phenotype of PD/DLB.
METHODS
37 RBD subjects underwent cardiac [123I]MIBG and brain [123I]FP-CIT-SPECT at baseline. Olfactory (Sniffin' Sticks), cognitive and motor functions were tested annually for ∼4 years.
RESULTS
29/37 (78.4%) subjects had a pathological [123I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [123I]FP-CIT-SPECT, always combined with a pathological [123I]MIBG. In subjects with pathological [123I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [123I]MIBG compared to those with normal [123I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [123I]MIBG and [123I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all- except for one- presented with at least moderate hyposmia at baseline.
CONCLUSION
A combination of the biomarkers "pathological [123I]MIBG" and "hyposmia" likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [123I]MIBG had a normal [123I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [123I]MIBG, olfactory impairment is progressive independent of the [123I]FP-CIT-SPECT status.
Identifiants
pubmed: 35754288
pii: JPD223201
doi: 10.3233/JPD-223201
pmc: PMC9535565
doi:
Substances chimiques
Tropanes
0
3-Iodobenzylguanidine
35MRW7B4AD
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1921-1935Références
Brain. 2020 Oct 1;143(10):3077-3088
pubmed: 32830221
Lancet Neurol. 2016 Apr;15(4):405-19
pubmed: 26971662
Eur Arch Otorhinolaryngol. 2000;257(4):205-11
pubmed: 10867835
Mov Disord Clin Pract. 2018 Nov 09;6(1):46-50
pubmed: 30746415
Neurology. 1999 Sep 22;53(5):1020-5
pubmed: 10496261
Neurology. 2015 Feb 17;84(7):654-8
pubmed: 25609758
Sleep. 2016 Jan 01;39(1):121-32
pubmed: 26940460
Parkinsonism Relat Disord. 2013 Jun;19(6):600-4
pubmed: 23529022
Ann Neurol. 2011 May;69(5):811-8
pubmed: 21246603
Clin Auton Res. 2015 Feb;25(1):69-75
pubmed: 25739474
Lancet Neurol. 2021 Aug;20(8):671-684
pubmed: 34302789
J Parkinsons Dis. 2022;12(3):983-991
pubmed: 35094998
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Brain. 2005 Jan;128(Pt 1):126-37
pubmed: 15548552
Mov Disord. 2010 May 15;25(7):936-40
pubmed: 20310038
Mov Disord. 2021 Jan;36(1):230-235
pubmed: 32909650
Neurology. 2006 Dec 26;67(12):2236-8
pubmed: 17190953
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Parkinsonism Relat Disord. 2010 May;16(4):252-5
pubmed: 20097595
Mov Disord. 2017 Oct;32(10):1482-1486
pubmed: 28734065
Sci Rep. 2018 May 8;8(1):7304
pubmed: 29740055
Mov Disord. 2003 Jul;18(7):738-50
pubmed: 12815652
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Sci Rep. 2019 Oct 29;9(1):15463
pubmed: 31664065
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
J Clin Sleep Med. 2014 Sep 15;10(9):1039-40
pubmed: 25221449
Sleep. 2002 Mar 15;25(2):120-38
pubmed: 11902423
Parkinsonism Relat Disord. 2010 Dec;16(10):683-5
pubmed: 20846893
Lancet Neurol. 2018 Jul;17(7):618-628
pubmed: 29866443
Sleep. 2013 Nov 01;36(11):1579-85
pubmed: 24179289
Mov Disord. 2006 Jul;21(7):916-23
pubmed: 16547944
Chem Senses. 1997 Feb;22(1):39-52
pubmed: 9056084
Ann Clin Transl Neurol. 2021 Jan;8(1):201-212
pubmed: 33321002
Brain. 2019 Jul 1;142(7):2051-2067
pubmed: 31111143
Eur J Neurol. 2017 Feb;24(2):349-356
pubmed: 27888574
Sleep. 2008 May;31(5):717-23
pubmed: 18517041
J Mov Disord. 2020 Jan;13(1):1-10
pubmed: 31694357
Sleep. 2015 Jun 01;38(6):907-17
pubmed: 25325487
Mov Disord. 2011 Jun;26(7):1218-24
pubmed: 21480373
Sleep Med. 2009 May;10(5):577-80
pubmed: 18752998
Nat Rev Dis Primers. 2018 Aug 30;4(1):19
pubmed: 30166532
Neurosci Bull. 2017 Oct;33(5):526-534
pubmed: 28776303
Sleep. 2017 Aug 1;40(8):
pubmed: 28472425
Brain. 2019 Mar 1;142(3):744-759
pubmed: 30789229
Ann Neurol. 2017 Sep;82(3):419-428
pubmed: 28833467